db101
2 years ago
The Company reported that on October 4, 2022, the Company purchased 38,035 shares of common stock at $6.99 per share. Anthony Hayes, CEO of AIkido stated, "We believe the Company stock continues to be undervalued and we are using this opportunity to enhance shareholder value by reducing the amount of stock that is outstanding."
TheFinalCD
3 years ago
AIkido owns 525,000 shares of DatChat, which it previously purchased for $500,000.00. As of September 13th, DatChat shares closed at $6.54, well higher than its IPO price and representing a more than 600% return or an additional $3,433,500.00 added to AIKI balance sheet. $AIKI
https://twitter.com/ohheytommy/status/1448004249493798912
georgie18
3 years ago
AIKI...86...Tue, July 27, 2021, 10:00 AM
AIkido's License to Technology Includes Targeted Psilocybin Treatment for Cancer Patients
NEW YORK, July 27, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for application No.: 16/477,125. This technology relates to the use of novel and proprietary central nervous system (CNS) homing peptides. This technology has been exclusively sublicensed to AIkido Pharma for use of psilocybin for the therapeutic treatment of neuroinflammatory disease in cancer patients.